Drugs / Renuva
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05880888 | Apr 2023 → Jan 2024 | — | Ohio State University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04700566 | May 2022 → Dec 2024 | voice disorders | University of Southern California | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Renuva | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04700566 ↗ |
| Modality | Other / unclassified | “injectable decellularized allograft adipose matrix (AAM)” NCT05880888 ↗ |
| Route | Other | “Unilateral injection augmentation with allograft adipose matrix injectable.” NCT04700566 ↗ |